Ignacio Garrido‐Laguna

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

  2025-11-25

• Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

  2025-11-25

• Supplementary Data 1 from Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC

  2025-11-25

• Abstract A081: Resistance Mechanisms to Monotherapy RAS(ON) Multi-Selective Inhibitor Daraxonrasib (RMC-6236) in RAS Mutant PDAC Inform Therapeutic Combination Strategies

  Molecular Cancer Therapeutics · 2025-10-22 · 1 citations

• Impact of DNA damage repair alterations on real-world response to therapy in metastatic colorectal cancer

  ESMO Open · 2025-09-01 · 1 citations

• 917O DS-3939, a tumor-associated mucin 1 (TA-MUC1)–directed antibody–drug conjugate (ADC), in patients (pts) with advanced/metastatic (adv/met) solid tumors: Initial results from a first-in-human (FIH) study

  Annals of Oncology · 2025-09-01

• Trial in progress: RASolute 302—A phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, versus standard of care chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).

  Journal of Clinical Oncology · 2025-05-28 · 9 citations

• Mechanisms of resistance to active state selective tri-complex RAS inhibitorsPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-04-26 · 10 citations

• Abstract LB218: Early reduction in circulating tumor DNA (ctDNA) is associated with clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)

  Cancer Research · 2025-04-25

• Abstract CT262: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656)

  Cancer Research · 2025-04-25 · 5 citations

• Abstract LB281: Mechanisms of resistance to the RAS(ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC and potential resolution with RAS(ON) combination therapies

  Cancer Research · 2025-04-25 · 7 citations

• Abstract 4608: Evaluation of the impact of homozygous MTAP truncations on the clinical activity of MTA-cooperative PRMT5 inhibitors

  Cancer Research · 2025-04-21

• 6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)

  Journal of Thoracic Oncology · 2025-03-01 · 15 citations

• Disparities in prophylactic tetracycline use among patients with metastatic colorectal cancer undergoing treatment with EGFR inhibitors.

  Journal of Clinical Oncology · 2025-01-27

• MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in <i>KRAS G12D</i> -mutant solid tumors.

  Journal of Clinical Oncology · 2025-01-27 · 5 citations

• Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC).

  Journal of Clinical Oncology · 2025-01-27 · 39 citations

• Cost-effectiveness of NALIRIFOX compared to other first-line treatments for metastatic pancreatic cancer.

  Journal of Clinical Oncology · 2025-01-27 · 1 citations

• <i>KRAS</i> Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma

  JAMA Network Open · 2025-01-07 · 34 citations

• Gemcitabine-induced myositis in a patient with pancreatic cancer

  BMJ Case Reports · 2025-01-01 · 3 citations

• Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’

  Nature Reviews Clinical Oncology · 2024-10-25